- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis
Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.
The Food and Drug Administration (FDA) has granted fast track designation for potential use of the positron emission tomography (PET) agent 18F(florbetaben) in the detection of cardiac amyloid light-chain (AL) and amyloid transthyretin-related (ATTR) amyloidosis.
Currently indicated for the estimation of beta amyloid neuritic plaque density on PET scans for patients being assessed for cognitive decline, 18F(florbetaben) (Neuraceq, Life Molecular Imaging) is currently the subject of a phase 3 multicenter trial for detection of cardiac amyloidosis, according to Life Molecular Imaging.
The positron emission tomography (PET) agent 18F(florbetaben) (Neuraceq, Life Molecular Imaging) is currently being evaluated in a phase 3 multicenter trial for detection of cardiac amyloidosis. The radiopharmaceutical 18F(florbetaben) was recently granted with the fast track designation by the FDA for the detection of cardiac amyloid light-chain (AL) and amyloid transthyretin-related (ATTR) amyloidosis. (Images courtesy of the Journal of Nuclear Medicine.)
“Diagnosing cardiac AL amyloidosis is complex and challenging,” added Andrew Stephens, MD, PhD, CMO of Life Molecular Imaging. “(18F)florbetaben PET imaging of patients with suspected cardiac amyloidosis has the potential to streamline the diagnostic process, providing earlier and appropriate access to therapy and improved monitoring of such interventions.”
Noting the safety profile of the radiopharmaceutical, Life Molecular Imaging said clinical trial research involving nearly 1,100 administrations of 18F(florbetaben) revealed that the most common adverse drug reactions were injection site pain in 3.4 percent of patients and injection site erythema in 1.7 percent of patients.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
